ADMA Biologics Inc (NASDAQ:ADMA) CMO James Mond Acquires 4,285 Shares

ADMA Biologics Inc (NASDAQ:ADMA) CMO James Mond bought 4,285 shares of the stock in a transaction dated Tuesday, February 11th. The shares were acquired at an average price of $3.50 per share, with a total value of $14,997.50. Following the completion of the purchase, the chief marketing officer now directly owns 22,174 shares of the company’s stock, valued at $77,609. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Shares of ADMA Biologics stock opened at $3.51 on Friday. The company has a debt-to-equity ratio of 2.33, a current ratio of 6.42 and a quick ratio of 3.76. ADMA Biologics Inc has a 1-year low of $3.03 and a 1-year high of $6.31. The business has a 50-day moving average of $4.05 and a 200-day moving average of $4.27. The company has a market capitalization of $205.24 million, a PE ratio of -3.16 and a beta of 2.62.

Several hedge funds have recently modified their holdings of the company. Vanguard Group Inc. lifted its position in shares of ADMA Biologics by 47.3% during the second quarter. Vanguard Group Inc. now owns 2,448,253 shares of the biotechnology company’s stock worth $9,474,000 after purchasing an additional 786,567 shares during the last quarter. BlackRock Inc. lifted its position in shares of ADMA Biologics by 94.0% during the second quarter. BlackRock Inc. now owns 1,897,484 shares of the biotechnology company’s stock worth $7,343,000 after purchasing an additional 919,260 shares during the last quarter. Millennium Management LLC lifted its position in shares of ADMA Biologics by 531.3% during the third quarter. Millennium Management LLC now owns 862,519 shares of the biotechnology company’s stock worth $3,838,000 after purchasing an additional 1,062,519 shares during the last quarter. State Street Corp lifted its position in shares of ADMA Biologics by 21.1% during the fourth quarter. State Street Corp now owns 843,366 shares of the biotechnology company’s stock worth $3,373,000 after purchasing an additional 146,962 shares during the last quarter. Finally, Motley Fool Asset Management LLC lifted its position in shares of ADMA Biologics by 19.2% during the fourth quarter. Motley Fool Asset Management LLC now owns 533,382 shares of the biotechnology company’s stock worth $2,134,000 after purchasing an additional 86,078 shares during the last quarter. 62.84% of the stock is currently owned by institutional investors and hedge funds.

Several analysts have recently weighed in on the company. BidaskClub downgraded ADMA Biologics from a “sell” rating to a “strong sell” rating in a research note on Wednesday, January 29th. HC Wainwright restated a “buy” rating on shares of ADMA Biologics in a research note on Wednesday, January 8th. ValuEngine upgraded ADMA Biologics from a “sell” rating to a “hold” rating in a research note on Wednesday. Finally, Maxim Group set a $12.00 target price on ADMA Biologics and gave the company a “buy” rating in a research note on Monday, October 21st. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $10.20.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.

Featured Article: Do You Need a Fiduciary?

Insider Buying and Selling by Quarter for ADMA Biologics (NASDAQ:ADMA)

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.